Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 620M 687M | Sales 2025 * | 811M 898M | Capitalization | 6.06B 6.71B |
---|---|---|---|---|---|
Net income 2024 * | 127M 141M | Net income 2025 * | 160M 177M | EV / Sales 2024 * | 9.67 x |
Net cash position 2024 * | 64.89M 71.88M | Net Debt 2025 * | 74.85M 82.9M | EV / Sales 2025 * | 7.57 x |
P/E ratio 2024 * |
50.5
x | P/E ratio 2025 * |
38.2
x | Employees | 2,006 |
Yield 2024 * |
1.06% | Yield 2025 * |
1.15% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 17 M€ | +6.09% | - |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |